- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Successful Use of Pulse IV Methylprednisolone in Epileptic Encephalopathy (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_514;
Pulse IV methylprednisolone is potentially a good and safe treatment option for children with EE, especially if considered early in their management. Further studies are needed to characterise the exact group of children this will benefit.
- |||||||||| Kineret (anakinra) / SOBI
Febrile infection-related epilepsy syndrome - case report (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_498;
A ketogenic diet and various antiepileptic drugs (levetiracetam, clobazam, lacosamide, topiramate, phenobarbital) were introduced... FIRES is rare but diagnostically and therapeutically challenging disorder which must be considered in the differential diagnosis of refractory status epilepticus.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Opsoclonus-myoclonus-ataxia syndrome: Two children with interesting similarities and literature review (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_323;
Early diagnosis followed by immediate and effective therapy is thought to be important for prognosis; however, substantial evidence for this hypothesis is still lacking. The presented cases followed by a literature review will enable attendees to recognize OMAS as a differential diagnosis and to initiate appropriate diagnostic and therapeutic approaches.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Pediatric MOGAD presenting with fulminant idiopathic intracranial hypertension (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_322;
The misdiagnosis is supported by lumbar puncture, showing an elevated opening pressure - resulting from underlying inflammatory processes. Correct diagnosis is mandatory with important treatment implication.
- |||||||||| prednisolone / Generic mfg.
Journal: Immunoglobulin G4-Related Bilateral Palpebral Conjunctival Involvement. (Pubmed Central) - May 29, 2023
The patient was given 30 mg of oral prednisolone daily, which was tapered gradually...The lesions subsided on both sides. On the basis of the literature review, normal serum IgG4 level and upper eyelid lesions may be features of IgG4-related bilateral palpebral conjunctival lesions, and systemic steroids may be effective for this entity.
- |||||||||| DuoResp Spiromax (budesonide/formoterol) / Teva
Journal: The match between adhesive mixture powder formulations for inhalation and the inhaler device. (Pubmed Central) - May 29, 2023
On the basis of the literature review, normal serum IgG4 level and upper eyelid lesions may be features of IgG4-related bilateral palpebral conjunctival lesions, and systemic steroids may be effective for this entity. To address this question, three budesonide-containing reservoir DPIs: Novopulmon Novolizer
- |||||||||| remdesivir / Generic mfg., dexamethasone / Generic mfg., voriconazole / Generic mfg.
Observational data, Retrospective data, Journal: Endogenous Fungal Endophthalmitis following COVID-19 Hospitalization: Evidence from a Year-Long Observational Study. (Pubmed Central) - May 29, 2023
These findings thus highlight a novel regulation of MafA oncogenic activity in MM and provide the rationale by targeting HERC4/GSK3?/MafA for the treatment of MM. Ophthalmologists should maintain a high index of clinical suspicion for EFE in cases with visual symptoms and a history of recent COVID-19 hospitalization and/or systemic corticosteroid use - even without other well-known risk factors.
- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Retrospective data, Journal: Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy. (Pubmed Central) - May 28, 2023
All participants underwent intravenous methylprednisolone (IVMP) therapy for a duration of 12 weeks...Furthermore, in cases of non-response to IVMP therapy, a diminished decline in both antibodies was observed, and elevated levels of TRAb and TSAb post-treatment were found to be a significant predictor of poor treatment outcome. Measurement of TRAb and TSAb throughout the course of treatment in moderate-to-severe and active cases of GO may offer valuable insights into treatment prognosis and aid in the decision-making process regarding the potential need for increased IVMP dosage or alternative therapeutic strategies.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly, remdesivir inhalation (GS-5734 inhalation) / Gilead
Journal: Autopsy Findings of Severe COVID-19 Pneumonia Combined with Pulmonary Aspergillosis, Pneumothorax, and Pulmonary Thromboembolisms. (Pubmed Central) - May 28, 2023
Despite oxygen inhalation, remdesivir, dexamethasone (6.6 mg per day), and baricitinib (4 mg per day for 12 days), the disease progressed...Dexamethasone was switched to methylprednisolone (1000 mg per day for 3 days, and then reduced by half every 3 days), and intravenous heparin was initiated...It is not easy to improve these conditions simultaneously because their treatments can induce antagonizing biological actions. To prevent severe COVID-19, it is important to reduce risk factors, such as by vaccination and appropriate blood glucose control.
- |||||||||| methylphenidate tablet / Generic mfg., methylprednisolone oral / Generic mfg., methamphetamine / Generic mfg.
Comparison of Behavioral Effects of Novel Designer Drugs in Male Rodents (Plaza Ballroom D) - May 28, 2023 - Abstract #CPDD2023CPDD_77;
However, abuse with N-cyclohexylmethylone may be unlikely due to its weak stimulant and discriminative stimulus 1 effects. In addition, N-cyclohexylmethylone and ?-D2PV produced convulsions, therefore pose additional dangers for recreational use.
- |||||||||| QN-165 / Qualigen Therap
Journal: Assessment of Aptamer as a Potential Drug Targeted Delivery for Retinal Angiogenesis Inhibition. (Pubmed Central) - May 27, 2023
AT11-L0 is an aptamer derivative of AS1411 composed of G-rich sequences that can adopt a G-quadruplex (G4) structure and target nucleolin (NCL), a protein that acts as a co-receptor for several growth factors...The aptamer-functionalized liposomes loaded with ligands C and dexamethasone did not show cytotoxic effects in HUVEC cells compared with the free ligands and AT11-L0, as assessed by cell viability assays...In addition, AT11-L0 did not show anti-angiogenic effects at the concentrations tested. However, C shows potential as an angiogenesis inhibitor, which should be further developed and optimized in future experiments.
- |||||||||| dexamethasone / Generic mfg.
Biomarker, Review, Journal: Cortisol and the Dexamethasone Suppression Test as a Biomarker for Melancholic Depression: A Narrative Review. (Pubmed Central) - May 27, 2023
An improved, standardized, and validated version of the DST would be a biologically meaningful and useful biomarker in psychiatry, providing a tool for clinicians caring for depressed patients in the areas of diagnosis, treatment, and prognosis, and predicting the risk of suicide. Additionally, such a test could be a crucial part in the generation of biologically homogenous patient cohorts, necessary for the successful development of new psychotropic medications.
- |||||||||| Triesence (triamcinolone acetonide injectable suspension) / Novartis, Ozurdex (dexamethasone intravitreal implant) / AbbVie
Journal: The Impact of Intraocular Treatment on Visual Acuity of Patients Diagnosed with Branch Retinal Vein Occlusions. (Pubmed Central) - May 27, 2023
The second group of 15 eyes received 3 intravitreal injections, the first and second with the anti-vascular endothelial growth factor aflibercept and the third one with 4 mg of triamcinolone acetonide (Vitreal S), spaced at one month...Six patients experienced transient raised intraocular pressure at one week after treatment. This study highlights the benefits to visual acuity of the combination of anti-vascular endothelial growth factor and cortisone, which represents a viable solution with similar results to Ozurdex therapy.
- |||||||||| dexamethasone / Generic mfg.
Journal: How Dexamethasone Used in Anti-COVID-19 Therapy Influenced Antihypertensive Treatment in Patients with SARS-CoV-2. (Pubmed Central) - May 27, 2023
This study highlights the benefits to visual acuity of the combination of anti-vascular endothelial growth factor and cortisone, which represents a viable solution with similar results to Ozurdex therapy. Dexamethasone for treatment of SARS-CoV-2 infection did not have a notable influence on increasing BP, because the doses were low-moderate and prescribed for a short time.
- |||||||||| dexamethasone / Generic mfg.
Journal: Myogenesis in C2C12 Cells Requires Phosphorylation of ATF6? by p38 MAPK. (Pubmed Central) - May 27, 2023
All these findings suggest that the p-p38 MAPK/ATF6? axis, in pathophysiological conditions, regulates myogenesis by promoting the exit from the cell cycle, an essential step to start myoblasts differentiation.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Parnassin, a Novel Therapeutic Peptide, Alleviates Skin Lesions in a DNCB-Induced Atopic Dermatitis Mouse Model. (Pubmed Central) - May 27, 2023
In the AD mouse model, topical administration of parnassin improved skin lesions and symptoms in AD mice, such as epidermal thickening and mast cell infiltration, similar to the existing treatment, dexamethasone, and did not affect body weight, or the size and weight of spleen...Parnassin also significantly reduced the gene expression of TSLP and IL-31, which are pruritus-inducing cytokines. These findings suggested that parnassin alleviates AD-like lesions via its immunomodulatory effects and can be used as a candidate drug for the prevention and treatment of AD because it is safer than existing treatments.
- |||||||||| prednisone / Generic mfg., budesonide / Generic mfg.
Journal: Collagenous gastritis in children: A national cohort. (Pubmed Central) - May 27, 2023
Collagenous gastritis is an exceptional condition, clinically manifested in children as abdominal pain and iron deficiency anemia probably of hemorrhagic origin. Patients require long-term follow-up and monitoring of their disease to describe the risk of progression better.
- |||||||||| hydroxychloroquine / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Journal: Severe Neonatal Interstitial Lung Disease Caused by a Rare Surfactant Protein C Mutation. (Pubmed Central) - May 26, 2023
Despite the treatment, his respiratory situation deteriorated continuously, leading to several hospitalizations and continuous escalation of noninvasive ventilatory support. At 6 months of age, the patient was listed for lung transplant and transplanted successfully aged 7 months.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Hydrocortisone in Severe Community-Acquired Pneumonia. (Pubmed Central) - May 26, 2023
P3
Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. (Funded by the French Ministry of Health; CAPE COD ClinicalTrials.gov number, NCT02517489.).
- |||||||||| ABBV-319 / AbbVie
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Adverse events: A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 26, 2023
P1, N=114, Recruiting,
(Funded by the French Ministry of Health; CAPE COD ClinicalTrials.gov number, NCT02517489.). Not yet recruiting --> Recruiting | Trial completion date: Sep 2026 --> Feb 2026 | Initiation date: Aug 2022 --> Apr 2023 | Trial primary completion date: Sep 2026 --> Feb 2026
- |||||||||| iberdomide (CC-220) / BMS
Enrollment closed, Combination therapy: Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov) - May 26, 2023
P1/2, N=18, Active, not recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Sep 2026 --> Feb 2026 | Initiation date: Aug 2022 --> Apr 2023 | Trial primary completion date: Sep 2026 --> Feb 2026 Recruiting --> Active, not recruiting
- |||||||||| MODULE 1: Multiple Myeloma (MM) (Hilton Chicago; Grand Ballroom (Level 2)) - May 26, 2023 - Abstract #ASCO2023ASCO_7060;
This activity is supported by educational grants from AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Karyopharm Therapeutics, Lilly, Regeneron Pharmaceuticals Inc, Sanofi, and Seagen Inc. Clinical and biological factors affecting the selection of up-front therapy for patients with MMLong-term findings with daratumumab-containing regimens for newly diagnosed MM; role for transplant-eligible and ineligible patientsPublished data with novel daratumumab-based quadruplet regimens for transplant-eligible patients with newly diagnosed MMSimilarities and differences between daratumumab and isatuximabKey findings from the Phase III GMMG HD7 trial comparing isatuximab with RVd to RVd alone for transplant-eligible patients with newly diagnosed MMOngoing Phase III studies of isatuximab as a part of induction therapy for transplant-eligible and ineligible patientsAvailable data with and current role of minimal residual disease assessment in therapeutic decision-makingOptimal maintenance approach for transplant-eligible and ineligible patientsResults from Phase III trials evaluating isatuximab-based combination regimens for relapsed/refractory (R/R) MMKey results from the Phase III BOSTON trial leading to the FDA approval of selinexor in combination with bortezomib/dexamethasone for R/R MM; available data with other selinexor-based combinationsStructural makeup and manufacturing of available B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell platformsEfficacy and safety findings from the KarMMa (idecabtagene vicleucel) and CARTITUDE-1 (ciltacabtagene autoleucel) trials for R/R MMAvailable and emerging data with and ongoing studies of BCMA-targeted CAR T-cell therapies in earlier lines of treatmentSimilarities and differences in the cellular targets and mechanisms of action of bispecific antibodies in MMActivity and responses observed with available (teclistamab) and investigational (elranatamab, linvoseltamab, ABBV-383) BCMA-targeted bispecific antibodies in R/R MMBiological rationale for and available data with non-BCMA-targeted bispecific antibodies (eg, talquetamab, cevostamab, forimtamig); FDA breakthrough therapy designation for talquetamabSpectrum, incidence and severity of toxicities, including cytokine release syndrome and neurotoxicity, with bispecific antibodies in patients with MM; mitigation and management protocolsPublished data with and current role of venetoclax-based therapy for patients with MM and t(11;14) or Bcl-2 overexpressionOther promising novel strategies in clinical development for patients with MM
- |||||||||| dexamethasone / Generic mfg., tetracycline / Generic mfg.
Journal: Lubricated Interfaces Enabling Simultaneous Pulsatile and Continuous Chemical Release Modes. (Pubmed Central) - May 25, 2023
Moreover, we can control the loading method of distinct molecules to program their release mode. Finally, we demonstrate the pulsatile and continuous release of two distinct bioactive small molecules, tetracycline and dexamethasone, which display antibacterial and immunomodulatory activities for applications such as chronic wound healing and biomedical implant coating.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Association of mortality with fludrocortisone addition to hydrocortisone treatment among septic shock patients: a propensity score matching analysis. (Pubmed Central) - May 25, 2023
After PSM, binomial Logistic regression analysis showed that SAPS II score was an independent risk factor for 28-day morality (OR?=?1.04, 95%CI 1.02-1.06, p <?0.01) and in-hospital morality (OR?=?1.04, 95%CI 1.01-1.06, p <?0.01), while hydrocortisone plus fludrocortisone was not an independent risk factor for 90-day mortality (OR?=?0.88, 95%CI 0.43-1.79, p =?0.72), 28-day morality (OR?=?1.50, 95%CI 0.77-2.91, p =?0.24), or in-hospital morality (OR?=?1.58, 95%CI 0.81-3.09, p =?0.18). In the treatment of patients with septic shock, hydrocortisone plus fludrocortisone did not reduce 90-day mortality, 28-day mortality, and in-hospital mortality compared with hydrocortisone alone, and had no effect on the length of hospital stay and ICU stay.
|
